What Woodford worries?

Why Woodford’s woes won’t discourage investment in U.K. biotech

A trio of U.K. life science investors don’t expect the recent lackluster performance of Neil Woodford to weigh on local biotechs looking to raise money.

The high profile investor’s largest fund, Woodford Equity Income Fund, saw

Read the full 358 word article

User Sign In